Suggested remit: To appraise the clinical and cost effectiveness of fruquintinib within its marketing authorisation for treating metastatic colorectal cancer.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6274

Provisional Schedule

Committee meeting: 1 11 July 2024
Expected publication 18 September 2024

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen


Companies sponsors Takeda (fruquintinib)
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
Patient carer groups Bowel Cancer UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Assessment group Aberdeen HTA Group
Associated public health groups None
Comparator companies Servier Laboratories (trifluridine-tipiracil) (confidentiality agreement signed, participating)
  Bayer (regorafenib) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
05 December 2023 Invitation to participate
10 October 2023 - 07 November 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6274
15 June 2023 In progress. DHSC referral received
07 February 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual